Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) on Monday, plunged -9.82% from the previous trading day, before settling in for the closing price of $3.87. Within the past 52 weeks, AMLX’s price has moved between $1.58 and $7.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 1970.62%. The company achieved an average annual earnings per share of 54.70%. With a float of $64.38 million, this company’s outstanding shares have now reached $68.63 million.
Let’s determine the extent of company efficiency that accounts for 123 employees. In terms of profitability, gross margin is -43.25%, operating margin of -334.07%, and the pretax margin is -345.81%.
Amylyx Pharmaceuticals Inc (AMLX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Amylyx Pharmaceuticals Inc is 27.34%, while institutional ownership is 56.46%. The most recent insider transaction that took place on Mar 03 ’25, was worth 14,483. In this transaction Co-Chief Executive Officer of this company sold 4,595 shares at a rate of $3.15, taking the stock ownership to the 3,196,648 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Co-Chief Executive Officer sold 4,595 for $3.17, making the entire transaction worth $14,549. This insider now owns 3,196,652 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 54.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.21% during the next five years compared to -78.71% drop over the previous five years of trading.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Amylyx Pharmaceuticals Inc (AMLX) is currently performing well based on its current performance indicators. A quick ratio of 6.67 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.43, a number that is poised to hit -0.50 in the next quarter and is forecasted to reach -1.88 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
Looking closely at Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), its last 5-days average volume was 1.22 million, which is a jump from its year-to-date volume of 0.88 million. As of the previous 9 days, the stock’s Stochastic %D was 78.30%. Additionally, its Average True Range was 0.34.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 19.06%, which indicates a significant decrease from 58.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 102.20% in the past 14 days, which was higher than the 86.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.55, while its 200-day Moving Average is $3.25. However, in the short run, Amylyx Pharmaceuticals Inc’s stock first resistance to watch stands at $3.79. Second resistance stands at $4.09. The third major resistance level sits at $4.33. If the price goes on to break the first support level at $3.26, it is likely to go to the next support level at $3.02. Now, if the price goes above the second support level, the third support stands at $2.72.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
Market capitalization of the company is 309.22 million based on 68,548K outstanding shares. Right now, sales total 380,790 K and income totals 49,270 K. The company made 420 K in profit during its latest quarter, and -72,700 K in sales during its previous quarter.
